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ABSTRACT 
Yeast like opportunistic fungal infection has been reported globally amongst HIV/AIDS patients, particularly as the etiologic agent of 
oral thrush. Fluconazole antibiotic has been most popularly employed in treating cases of oral thrush in HIV/AIDS patients. Recent 
reports have recorded antifungal drug resistance amongst immunocompromised subjects. This constitutes a big problem in the 
management of opportunistic candidiasis. The NCCLS micro/macrodilusion sensitivity testing procedure is expensive, cumbersome 
and requires a level of sophistication. This study was designed to compare NCCLS M-27-A macrodilution method (expensive) with 
agar diffusion technique (cheap and simple), to provide a reliable rapid alternative to the new pressing need for antifungal routine 
sensitivity testing. Sputum specimens from 213(108 females and 105 males) HIV positive patients were plated onto SDA. The isolates 
were identified by morphotyping, microscopy and speciated using germ tube test, and battery of biochemical sugar fermentation; and 
assimilation tests. Fluconazole agar diffusion susceptibility testing was carried out on each isolate, compared with the NCCLS 
macrodilution sensitivity assay standard.  
 
Of the 74 isolates tested for fluconazole sensitivity, 59(79.7%) were sensitive (zone diameter > 19mm, mean diameter 28mm), 6(8.1%) 
were Sensitive Dose Dependent (S-DD) (zone diameter 13-18mm, mean diameter 16mm), while 9(12.2%) were resistant (zone diameter 
< 12mm) using agar diffusion method, matched with 58(78.4%) sensitive MIC < 8μg/ml, 9 (12.2%) S-DD MIC 16-32μg/ml and 7(9.5%) 
resistant MIC >64μg/ml profile, using the NCCLS macrodilution assay. The differences between the test method (Agar diffusion) and 
the control standard method (NCCLS-M 27-A broth Macrodilution MICS) were not statistically significant using t-test (two tail) (t = 
4.302656, P=1.0). Among the C. albicans isolates, 26(86.7%) were sensitive to fluconazole. The rank of susceptibility was C. albicans > 
C. tropicalis > C. krusei.    
 
It is concluded that broncho-oro-pharyngeal Candida and other yeast-like species existed in about one third of the HIV and AIDS 
patients studied; in which C. albicans was the most prevalent, while about ten percent of all the Candida isolates were resistant to 
fluconazole. The reliability of germ tube production as a confirmatory test for Candida albicans in HIV infection was as high as 96.7% 
and is therefore, recommended for continued use. Agar diffusion compared favourably with the NCCLS macrodilution technique, 
hence it is recommended for routine antifungal sensitivity test on all isolates of yeast-like cells from HIV and AIDS subjects. 
 
KEY WORDS: HIV/AIDS, oral thrush, yeast-like cells, fluconazole resistance, NCCLS vs agar diffusion technique.  
 
INTRODUCTION 
Fungal infections have been reported from the early 
days of HIV|AIDS epidemic (Hody-son and 
Rachanis, 2002). In USA death due too mycoses 
increased from 10th most common infectious disease 
in 1980 to the 7th. in 1997 (Mc-Neil, et al 2001). 
The rates of mortality for different mycoses varied 
markedly according to the HIV status, but were 
consistently higher among males, blacks and age 
group ≥ 65 years of age. (Mc-Neil, et al 2001; 
Lamagni, et al 2001). 
 
Mucosal candidiasis is prevalent in HIV infection 
and occurs in almost all the patients at sometime 
during the course of the HIV disease (Odds, 1994). 
Oropharyngeal Candidiasis (OPC) occurs in about 
84% of the cases (Neil, 1996).  Esophageal 
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candidiasis (EC) and OPC remain the most common 
opportunistic infection of those infected with HIV 
and are considered ‘AIDS Defining Illness (ADI) 
(Macher 1988; Jabrarisk, et al 2004). 
 
Candida albicans (Maenza et al, 1996; Dobosz and 
Marczynska 2004) is the most implicated. Yeast-like 
cells are found globally, some occur as normal flora 
(C. albicans) in wet areas (cavity, genitalia, large 
intestine and skin) of about 20% of humans. 
 
Other possible etiologic agents of oral thrush 
include C. krusei, C. tropicalis, C. parapsilosis, and  
C.  glabrata (Hauman, et al 1993; Klein, et al 1984; 
Odds, 1994). 
 
Azole, particularly fluconazole antfungal agent has 
been the most effective drug in the treatment of 
yeast-like infections (White, et al 2002). 
 
Antifungal drug resistance is fast becoming a major 
problem, particularly the fluconazole amongst the 
immunocompromised population ( Jabra Rizk, et al 
2004). According to Maenza, et al (1996), the major 
risk factors for fluconazole resistance were 
advanced immunosuppression and prolonged 
exposure to azoles (Andrew 2003). Again, Jones, et 
al (1994) and Vargas, et al (2000) confirmed 
switching on oral candida isolates from HIV|AIDS 
patients at frequency between one and two orders of 
magnitude higher than those of healthy control. 
 
Lynch and Sobel (1994) reported several fold 
increase in MICs to azoles tested, 0.31-40.0µg|ml 
for fluconazole. Carrillo-Munoze, et al reported 
mean MIC of 5.53µg|ml in 1999 on various yeast-
like cells. 
 
The newer classes of antifungal drugs – the 
echinocardins, pnemocardins and others are quite 
expensive and are not available in Nigeria. 
 
The increased reports of anticandidal resistance and 
the expanding drug therapy options prompted the 
need for clinically relevant antifungal susceptibility 
testing (Lewis, et al 1998). 
 
The NCCLS method is expensive, time consuming 
and somehow sophisticated as stated before. Other 
method like the E-test strip is easier but marred by 
high discrepancies, having only about 74.5% 
reproducibility. 
 
Currently, very few studies have been carried out on 
the effectiveness of the new trend in the 
management of EC, OPC and other mucosal fungal 
infections including chemotherapy and drug 
sensitivity pattern of yeast-like isolates from 
immunocompromised (HIV|AIDS) population in 
Nigeria in particular and Africa in general. 
 
This study was therefore designed to compare the 
NCCLS M 27 A macrodilusion sensitivity testing 
method with agar diffusion technique for easy and 
routine use in HIV/AIDS opportunistic infections 
diagnostic laboratories. 
MATERIALS AND METHOD 
ORGANISMS 
A total of 74 isolates were recovered from 213 adult 
patients presented with oral disorder attending ARV 
clinic for the first time between October, 2004 to 
December, 2005. 
 
Isolates were identified by grams reaction, germ 
tube and battery of biochemical sugar assimilation 
and fermentation tests (Rohde and Hartmann et al 
1980; Claderone, 2002). Isolates were stored as 
water suspensions until used (Pfaller, 1999). Prior to 
sensitivity testing, each isolate was passaged onto 
2% glucose Sabouraud Dextrose Agar (SDA) 
(OXOID), supplemented with chloroamphenicol 
(50mg|L) ( Rejane, et al, 2002) to ensure purity and 
viability. Cell suspension adjusted to the turbidity of 
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a 0.5 McFarland standard, as described by NCCLS 
for Candida species were used. 
 
SUSCEPTIBILITY TESTING  
Reference antifungal powder marked ‘Physicians 
sample’ was obtained from Pfizer pharmaceuticals 
Lagos, Nigeria. Macrodilution susceptibility was 
performed according to NCCLS M-27-A Standard. 
The MIC end points were read visually following 72 
hours incubation. The interpretative criteria for 
fluconazole were those published by NCCLS (2002) 
and are: susceptible, MIC ≤ 8µg|ml, susceptible 
dose dependent (SDD), MIC 16-32µg|ml and 
resistance ≥ 64µg|ml. 
 
For agar diffusion, 150mm diameter plates 
containing Mueller-Hinton agar (Difco 
Laboratories) supplemented with 2% glucose and 
methylene blue (0.5µg|ml) at a depth of 4mm were 
used. The solid agar surfaces were inoculated from 
the test organism suspension employed in the 
corresponding macrodilution procedure, before the 
holes were made. In the holes 0.1ml of the various 
concentrations of the fluconazoles were dispensed. 
The plates were incubated in the air at 35 ○C, read 
first at 24 hours and subsequently at 72 hours. 
 
The interpretative criteria for fluconazole agar test 
were those published by Pfaller, et al (1999): 
Sensitive, zone diameter of ≥ 19mm, SDD, zone 
diameter of 15-18mm, and resistant, zone diameter 
of ≤ 14mm. 
 
QUALITY CONTROL 
Quality control (QC) was performed in accordance 
with, the NCCLS recommendations, however, in 
place of C. parapsilosis ATTC 22019 (22-33mm) 
recommended, C. parapsilosis previously isolated in 
Lagos from an AIDS patient that clinically 
responded to a single dose of fluconazole without a 
repeat episode in 6 months was used; whose zones 
of inhibitions were consistently 20-40mm for all 
MICs 0.625-64µg/ml.This was included in all the 
assays to check the accuracy of the drug dilution and 
the reproducibility of the results. 
 
RESULTS 
Seventy three (34.7%) out of the 213 patients gave 
positive culture results for yeast-like species. One 
patient out of the culture positive ones harbored 
double yeast-like cells which were identified 
separately, bringing the total number of isolates to 
74.  Only 70(94.6%) of the isolates could be 
adequately speciated. Candida albicans 30 (40.5%), 
was the most frequently isolated species, the rest 
were non-Candida albicans Candida (NCAC) 
species, Table 4. 
 
The gender distribution, prevalence, species 
distribution and Frequency of the isolates have been 
published in a different report. 
 
Out of the 74 isolates tested for fluconazole 
sensitivity, 59(79.7%) were sensitive (zone diameter 
≥ 19mm [mean diameter 28mm]) 6(8.1%) were 
susceptible dose dependant (S-DD) (zone diameter 
13-18mm [mean diameter 16mm]} , while 9(12.2%) 
were resistant (Zone diameter ≤ 12mm} using agar 
diffusion technique table 1, compared with 
58(78.4%} sensitive MIC ≤ 8µg|ml, 9(12.2%) SDD 
MIC 16-32µg|ml and 7(9.5%) resistant MIC > 
64µg|ml using NCCLS macrodilution assay method 
Table 2. Table 3 shows the comparative analysis of 
both methods. The discrepancies between the two 
approaches were not statistically Significant using t-
test (two tail) (t=4.302656, p=1.0). 




TABLE 1:  25 µg/ml AVERAGE ZONE OF INHIBITION PROFILE 
 
SENSITIVE 
DIAMETER (≥ 19mm) 
 
 





P.CODE        DIAMETER    
RESISTANCE 
DIAMETER ≤ 12mm 
 
 
P.CODE            DIAMETER 
MR/10/01 39.0 MR/1/44 38.0      LU/11/21 14.5  MR/10/02  
MR/10/03 29.0    ID/1/45 31.5      MR/1/42 17.5  LU/10/08  
MR/10/04 38.5    ID/1/46 29.0       MR/1/43 13.0  LU/11/17  
MR/10/01 38.5    ID/1/47 27.5      ID/1/50 18.0  LU/11/20  
MR/10/06 24.0    ID/1/48 34.0      LU/1/54 17.5  MR/12/23  
LU/10/07 3.8    ID/1/49 32.5      MR/2/59 13.0  MR/12/26  
LU/10/09 18.5    ID/1/51 18.5      MR/12/33  
LU/10/10 41.0    ID/1/52 21.0      MR/2/58  
MR/11/11 30.0    ID/1/53 22.0      LU/2/66   
MR/11/12 29.5    LU/1/55 22.5 
MR/11/13 20.5    LU/1/56 29.5 
MR/11/14 24.0    LU/1/57 38.0 
MR/11/15 23.5   MR/2/60 18.5 
MR/11/16 32.5   MR/2/61 24.0 
MR/11/18 25.5   MR/2/62 21.0 
MR/11/19 41.0   MR/2/63 26.0 
MR/11/22 31.5   LU/2/64 22.0 
MR/12/24 32.5   LU/2/65 29.5 
MR/12/25 21.5   LU/2/67 36.5 
MR/12/27 19.0   ID/2/68 24.0 
MR/12/28 23.5   ID/2/69 24.0 
MR/12/29 19.0   ID/2/70a 29.0 
MR/12/30 27.5   ID/2/70b 25.0 
MR/12/31 19.5   ID/2/71 24.5 
MR/12/32 20.0   ID/2/72 27.5 







 MR/1/41 29.0  
Total    n = 59   n  =  6   n  =  9 
 
 Key: P CODE= Patients’hospital code number, MR= Medical Research, ID= Infectious Disease hospital 
and LU= LUTH hospital. 
 91
TABLE 2 
THE MICs OF MACRODILUTION PROCEDURE CONDUCTED 
 
SENSITIVE 
MIC  ≤  8µg/ml 
S-DD 
MIC  › 8 -32µg/ml 
RESISTANT 
MIC >  64µg/ml 
P-CODE         MIC P-CODE      MIC P-CODE      MIC P-CODE                
MIC 
MR/10/01       0.625 MR/1/43 8.0 MR/10/02 32  LU/10/08 >64 
MR/10/03       0.1 ID/1/45 0.25 MR/10/06 >8  LU/11/17 - 
MR/10/04       0.25 ID/1/46 1.0 MR/12/27 >8  LU/11/20 >64 
MR/10/05       0.25 ID/1/47 1.0 MR/11/33 32  MR/12/23 - 
MR/10/07       1.0 ID/1/48         0.25 LU/12/36 32  MR/12/26 - 
LU/10/09       4.0 ID/1/49     1.0         MR/11/44 32  MR/2/58 - 
LU/10/10       1.0 ID/1/50     8.0         ID/1/51 >8  LU/12/66 - 
MR/11/11       0.25 ID/1/52 0.25         MR/2/59 32 
MR/11/12       0.625 ID/1/53 1.0         MR/2/60 32 
MR/11/13       4.0 LU/1/54 8.0 
MR/11/14       1.0 LU/1/55 8.0 
MR/11/15      4.0 LU/1/56 0.25 
MR/11/16      1.0 LU/1/57 0.625 
LU/11/18      1.0 MR/2/61 4.0 
LU/11/19      0.25 MR/2/62 1.0 
LU/11/21      4.0 LU/2/63 1.0 
LU/11/22      0.25 LU/2/64 4.0 
MR/12/24      1.0 LU/2/65 1.0 
MR/12/25      0.25 ID/2/67 0.25 
MR/12/28      4.0 ID/2/68 1.0 
MR/12/29      1.0 ID/2/69 4.0 
MR/12/30      4.0 ID/2/70a 0.25 
MR/12/31      8.0 ID/2/70b 1.0 
MR/12/32      4.0 ID/2/71 0.25 
LU/12/34        0.25 ID/2/72 4.0 
LU/12/35        4.0 ID/2/73 0.25 
LU/12/37       1.0   
MR/1/38        0.25 
MR/1/39        4.0 
MR/1/40        4.0 
MR/1/41        0.25 
MR/1/42        8.0 
Total       n = 58       n = 9  n = 7 
Key: P.CODE= Patients’ hospital code number, MR= Medical Research, ID= Infectious Disease 
hospital and LU= LUTH hospital. 
 
 
TABLE 3: The COMPARATIVE ANALYSIS OF NCCLS MACRODILUTION AND AGAR 
DIFFUSION METHODS FOR FLUCONAZOLE SENSITIVITY PROFILE. 
 
METHOD               SENSITIVE             S-DD              RESISTANT      TOTAL                      
                                        n( %)                 n ( %)                n ( %)                n( %) 
 
NCCLS MACRO 
DILUTION                    58 (78.4)              9 (12.2)               7(9.4)           74(100) 
 
AGAR ZONE 
DIAMETER                 59(79.7)                 6 (8.1)               9(12.2)           74(100) 
 
T-test (two tail)   t = 4.3027, P = 1.0 
 
S-DD    =      Sensitive Dose Dependent. 
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TABLE 4: THE NCCLS MACRODILUTION FLUCONAZOLE SUSCEPTIBILITY PROFILES OF 
VARIOUS YEAST-LIKE SPECIES ISOLATED 
CANDIA                       NO ISOLATED       SENS.          SENS. DD    RESISTANT  
SPECIES                                                  NO  (%)         NO   (%)         NO (%) 
                                    
C .albicans                 30  26  86.7 1 3.3 3          10 
C. tropicalis               13                 11 84.6      1  7.7      1 7.7 
C. krusei                    5                  2 40.0      1          20.0     2 40 
C. glabrata                  4                   4 100          -                    -  
C.pseudotropicalis      3                    1 33.3       2  66.7    - 
C.parapsilosis             3                1 100        2 66.7    - 
C. famata                    3                    3  100                   -                   - 
C. kefyre                    2                    2          100          -                    -  
C.gulliermondii          1                     1 100                   -            - 
R. rubra                      1                 1 100                   -                      - 
T. cutaneum               1                   -                     -            1 100 
C. dubliniensis         1                    -    1 100 -            - 
C. neoformance         4                    3 75            1     25        - 
Indeterminate            3                    3 100                  -                         - 
 




Oral thrush caused by yeast-like organisms having 
been reported as a common opportunistic infection 
amongst immunocompromised HIV and AIDS 
patients requires a closer marking. 
 
That Candida albicans (40.5%) was the most 
implicated has equally been reported by Ehrahim, et 
al (2002) and Rejane, et al (2002); 52.4% and 57.4% 
from Bahraim and Brazil respectively. 
 
Essentially, it has been reported that all species of 
candida isolates from HIV and AIDS patients in 
America are potentially pathogenic (Jabria-Rizik, et 
al (2004); Colman, (1998).   However, the 
knowledge of the particular species involved in any 
episode is imperative, since some species of yeasts 
are known to be intrinsically resistant to some 
antifungals eg C. krusei to fluconazole (Regane, et 
al 2002). Azole(Fluconazole in particular) is 
considered the drug of choice for the treatment of 
oral candidiasis associated with HIV and AIDS 
patients ( White, et al 2002). 
 
Recent reports have indicated development of yeast-
like cells resistance to fluconazole antifungal 
(Gabriel, 1991; Maenza, et al 1996; White, et al 
2002; Sangeorzan, et al 1994 and Jabra-Rizk, et al 
2004). Factors associated with the development of 
yeast-like cells resistance have been severally 
reported to include include: Secondary (after 
previous drug exposure) resistance, prolonged 
clinical treatment, low dosage and advanced 
immunosuppression (Million, et al 1994; White, et 
al 2002).   These factors are gradually indicated in 
Nigerian ARV clinics. 
 
From the result of this study, 9.5% of clinical 
isolates of oral thrush yeast-like organisms showed 
invitro resistance to Fluconazole in Nigeria. This 
report is in agreement with Million et al who 
reported 5-10% in 1994 from Europe ,but lower than 
6- 36% reported by Priscila de Laet Sant’ Ana, et al 
from Brazil, in 2002. This could be explained in 
concord with the peer notion that there exist 
intrinsic and geographical differences amongst 
yeast-like organisms (Jabra-Rizk et al 2000), or that 




The sensitive C. albicans isolates had a mean MIC 
of 2.2µg/ml, (standard ≤ 8µg/ml) for macro and 
microdilution methods. Lynch and Sobel (1994) 
reported MIC of Fluconazole tested as 0.31 – 
40.0µg/ml, Pfaller; et al (1999) reported 1.25 -
2.5µg/ml for C. albicans.  And 5.0 – 50.0µg/ml for 
C. glabrata; and Carrillo-Munoze et al (1999) 
reported mean MIC of 5.53µg/ml. This relatively 
lower MIC reported here may be attributed to less 
abuse of the antifungal agent in the area studied, 
probably because it is not common unlike common 
antibacterial agents and the drug is somewhat 
expensive. 
Having established the need for fluconazole 
susceptibility tests on clinical isolates of yeast cells, 
this report put the resource poor setting into 
perspective, comparing the NCCLS drug sensitivity 
testing standard (macrodilution) with agar diffusion 
method. 
From the result of this study there are: 59 versus 58 
Sensitive (S) group, 6 versus 9 Sensitive Dose 
Dependant (S-DD) and 9 versus 7 Resistant group 
(R). The discrepancies between the standard method 
(The NCCLS M27-A broth macrodilution method) 
and the agar diffusion method were essentially 
minor using t-test (two tailed), t = 4.302656, p = 1.0. 
This report agrees with the work of Drussel, et al 
(1998) who reported complete agreement in 
percentage of the comparative study of disc 
diffusion method and NCCLS microdilution 
method. 
 
Since there are reports of intrinsic and geographical 
differences between different populations of yeast 
cells and with the report of extensive variety in yeast 
species recovered from Nigeria by Jabra-Rizk et al 
in 2000, this report recommends intermittent if not 
routine susceptibility testing of all-yeast-like 
isolates, particularly from immunocompromised 
(HIV/AIDs) subjects using less cumbersome and 
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